Following Tuesdays big announcement in the medical community I felt I had to do a quick write up about it.  If you’ve been following the world of women’s health, you’ve likely seen the headlines: Polycystic Ovary Syndrome (PCOS) is getting a massive rebrand. On May 12, 2026, a global consortium officially announced that the condition is being renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS).

This isn’t just a cosmetic update to the medical textbooks. It represents a fundamental shift in how we understand, diagnose, and treat a condition that affects nearly 170 million people worldwide. 

Why the Name Change Was Necessary

The name “PCOS” for a long time has been misleading and a misnomer.  I for one am excited for the condition to get a more accurate description of what is actually happening and here is why:

• Confusing: The term “polycystic” implies that the ovaries are covered in dangerous cysts. In reality, those “cysts” are actually small, underdeveloped follicles (egg sacs). You can have “PCOS” without these follicles, and you can have the follicles without having the syndrome.
• It’s more than just the ovary: By keeping “Ovary” as the primary focus, the old name suggested this was purely a reproductive or gynecological issue. This led many people to believe that if they weren’t trying to get pregnant, the condition wasn’t a priority.
• Metabolic: PMOS is, at its core, a multisystem disorder. It affects how your body processes insulin, how you gain or lose weight, your skin, your hair growth, and your long-term heart health.

What “PMOS” Actually Stands For

The new name acts as a much more accurate roadmap for the condition:

• Polyendocrine: Multiple hormones are out of balance (including insulin and androgens like testosterone).
• Metabolic: Highlights the impact on the body’s chemistry, energy use, and insulin sensitivity.
• Ovarian: Maintains the link to the reproductive system while acknowledging it is only one piece of the puzzle.
• Syndrome: Acknowledges the collection of diverse symptoms that look different for everyone.

---

Scientific Resources & Reading

The renaming is the result of a 14-year global consensus process involving over 14,000 patients and health professionals. You can read the official scientific documentation and announcements here:

• The Lancet: Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process – The primary scientific paper detailing the research and reasoning behind the change.
• The Endocrine Society: Official Press Release on the Renaming – Details on how the new name will improve diagnosis and care for the 1 in 8 women affected globally.
• Monash University: PCOS has a new name: Why it matters – Insights from Professor Helena Teede, who led the global naming consortium.
• University of Colorado Anschutz: Global Experts Rename PCOS to PMOS – A look at the clinical implications for future treatment and research.

What Happens Now?

We are currently in a three-year transition period. You’ll see both names used interchangeably in doctors’ offices, on insurance forms, and in support groups. The new name will be fully implemented in the 2028 International Guideline update.

While your current treatment plan won’t change overnight, the hope is that this new name will lead to faster diagnoses, better research funding, and a more holistic approach to care.

If you’re curious over on the podcast in 2025 we did an episode on PCOS and eating disorders with our guest Mary-Lauren Shelton Vise RDN, LD, CEDS. Listen here